Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Jitka Fucikova; Lenka Palova-Jelinkova; Vanessa Klapp; Peter Holicek; Tereza Lanickova; Lenka Kasikova; Jana Drozenova; David Cibula; Beatriz Álvarez-Abril; Elena García-Martínez; Radek Spisek; Lorenzo Galluzzi

doi:10.1016/j.trecan.2022.01.010

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Jitka Fucikova^*
, Lenka Palova-Jelinkova
, Vanessa Klapp
, Peter Holicek
, Tereza Lanickova
, Lenka Kasikova
, Jana Drozenova
, David Cibula
, Beatriz Álvarez-Abril
, Elena García-Martínez
, Radek Spisek
, Lorenzo Galluzzi

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

25 Citations (Scopus)

Abstract

At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8⁺ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.

Original language	English
Pages (from-to)	426-444
Number of pages	19
Journal	Trends in Cancer
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/j.trecan.2022.01.010
Publication status	Published - May 2022
Externally published	Yes

Keywords

PARP inhibitors
antiangiogenic agents
bevacizumab
immunogenic cell death
platinum derivatives
taxanes

Access to Document

10.1016/j.trecan.2022.01.010

Cite this

@article{dc468a225ecf4421a200632219ea11bd,

title = "Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents",

abstract = "At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.",

keywords = "PARP inhibitors, antiangiogenic agents, bevacizumab, immunogenic cell death, platinum derivatives, taxanes",

author = "Jitka Fucikova and Lenka Palova-Jelinkova and Vanessa Klapp and Peter Holicek and Tereza Lanickova and Lenka Kasikova and Jana Drozenova and David Cibula and Beatriz {\'A}lvarez-Abril and Elena Garc{\'i}a-Mart{\'i}nez and Radek Spisek and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = may,

doi = "10.1016/j.trecan.2022.01.010",

language = "English",

volume = "8",

pages = "426--444",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

AU - Fucikova, Jitka

AU - Palova-Jelinkova, Lenka

AU - Klapp, Vanessa

AU - Holicek, Peter

AU - Lanickova, Tereza

AU - Kasikova, Lenka

AU - Drozenova, Jana

AU - Cibula, David

AU - Álvarez-Abril, Beatriz

AU - García-Martínez, Elena

AU - Spisek, Radek

AU - Galluzzi, Lorenzo

PY - 2022/5

Y1 - 2022/5

N2 - At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.

AB - At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.

KW - PARP inhibitors

KW - antiangiogenic agents

KW - bevacizumab

KW - immunogenic cell death

KW - platinum derivatives

KW - taxanes

UR - https://www.scopus.com/pages/publications/85124669793

U2 - 10.1016/j.trecan.2022.01.010

DO - 10.1016/j.trecan.2022.01.010

M3 - Review article

C2 - 35181272

AN - SCOPUS:85124669793

SN - 2405-8033

VL - 8

SP - 426

EP - 444

JO - Trends in Cancer

JF - Trends in Cancer

IS - 5

ER -

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this